Annovis Bio Sets October 14 Vote to Double Authorized Shares to 140M
ANVS is trading near its 52-week low of $1.1 (1.3% above the low) on elevated volume (2.1× avg).
Summary
Annovis Bio's definitive proxy sets an October 14 special meeting to vote on doubling authorized shares to 140 million, a move that clears the way for future capital raises needed to fund its Phase 3 Alzheimer's trial.
Key Events · Corporate Governance and Compliance · ANVS
-
Authorized Shares Would Double to 140M
Proposal 1 seeks to increase authorized common stock from 70 million to 140 million shares and preferred stock from 2 million to 10 million. With 42.7 million shares outstanding and 21.2 million reserved for options and warrants, only 6.1 million shares remain available.
-
Special Meeting Set for October 14
Shareholders of record as of September 4, 2026 will vote at a virtual special meeting on October 14, 2026. Proposal 1 requires a majority of all outstanding shares, making broker non-votes effectively votes against.
-
Equity Plan Ratification Due to Typo
Proposal 2 ratifies a prior amendment to the 2019 Equity Incentive Plan. The original proxy incorrectly stated the increase was 1 million shares when it was actually 2.5 million, bringing the total plan reserve to 5.5 million shares.
-
Capital Raise Prerequisite
The company states the additional authorized shares are needed to raise capital for ongoing clinical trials. Annovis has a going concern warning and reported $18.7 million in cash as of Q2 2026.
Analysis · ANVS · Life Sciences
Annovis Bio is asking shareholders to approve doubling authorized common stock from 70 million to 140 million shares and increasing preferred stock from 2 million to 10 million. With 42.7 million shares outstanding and roughly 21.2 million shares already reserved for options and warrants, the company has only about 6.1 million shares left for future issuance. The company has a going concern warning and needs capital to fund its Phase 3 Alzheimer's trial, so this authorization is a prerequisite for future dilutive financings. The proxy also seeks ratification of a prior equity plan amendment that was misstated due to a typographical error — the actual increase was 2.5 million shares, not 1 million.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $1.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $47.7M. The 52-week trading range was $1.10 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.